FAQ: Soligenix's HyBryte™ Therapy for Cutaneous T-Cell Lymphoma (CTCL)
Summary
Soligenix is advancing HyBryte™ (synthetic hypericin) as a potential first-line treatment for early-stage cutaneous T-cell lymphoma (CTCL) through promising results from its FLASH trial and ongoing FLASH 2 confirmatory study. If successful, HyBryte could become the first approved front-line therapy for early-stage CTCL, reshaping standards of care and strengthening Soligenix's position in rare dermatologic oncology.
What is HyBryte™ and what condition does it treat?
HyBryte™ (also known as SGX301) is a novel photodynamic therapy using synthetic hypericin for the treatment of cutaneous T-cell lymphoma (CTCL). It is a non-UV light-activated therapy being developed as a potential first-line treatment for early-stage CTCL.
What are the key clinical trial results for HyBryte™?
In the original FLASH study, nearly half of patients showed meaningful response at 18 weeks, and interim results from an independent University of Pennsylvania study reported a 75% response rate. The ongoing FLASH 2 confirmatory study builds on these findings with improved design.
Why is HyBryte™ considered significant for CTCL treatment?
HyBryte™ offers hope in a field where therapeutic innovation has lagged and could become the first approved front-line therapy for early-stage CTCL, reshaping standards of care. It has demonstrated statistically significant efficacy and safety in clinical trials.
What is Soligenix Inc. and what is their focus?
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Their Specialized BioTherapeutics segment is advancing HyBryte™ for CTCL treatment.
What other development programs does Soligenix have?
Soligenix is expanding synthetic hypericin into psoriasis, developing dusquetide for inflammatory diseases including oral mucositis, and has vaccine programs including RiVax® for ricin toxin, filovirus vaccines, and CiVax™ for COVID-19 prevention using their ThermoVax® heat stabilization technology.
How is Soligenix’s research funded?
The company’s Public Health Solutions business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
Where can I find more information about Soligenix and their developments?
For further information, visit the company’s website at www.Soligenix.com or view the latest news and updates relating to SNGX in the company’s newsroom at https://ibn.fm/SNGX.
What is the current status of HyBryte™ development?
HyBryte™ is advancing through clinical trials with promising results from the pivotal FLASH trial and an ongoing FLASH 2 confirmatory study. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 264431